.png?w=3840)
Germany
,Stuttgart, April 3, 2023
Exyte announces completion of minority investment by BDT Capital Partners
Exyte, a global leader in the design, engineering, and delivery of high-tech facilities, today announced the completion of the previously announced transaction where funds affiliated with BDT Capital Partners, LLC (“BDT”), an affiliate of BDT & MSD Partners, have acquired a significant minority interest in Exyte. The transaction, which was first announced in November 2022, closed following receipt of all customary regulatory approvals. The Austrian Stumpf Group, who acquired Exyte in 2008, retains a majority stake in the company.
- Following the receipt of all required regulatory approvals, the transaction closed on March 31, 2023
- Having BDT as additional shareholder supports Exyte's long-term strategy and focus on high-tech industries
BDT’s shareholding supports Exyte’s long-term strategy. In fiscal year 2022, Exyte achieved sales of 7.4 billion euros, representing a 50 percent increase compared to 2021. As a leading provider of design, engineering, and construction services for high-tech industries, Exyte has targeted 10 billion euros in sales by 2027.
Georg Stumpf said: “BDT Capital Partners and the Stumpf Group are the perfect partners to further support the successful development of Exyte. I look forward to the long-term cooperation and a promising future.”
“We look forward to working with Exyte’s management team to support the company’s continued growth as it executes against its strategy,” said Don McLellan, Partner at BDT & MSD Partners. “This partnership is emblematic of our approach providing aligned long-term capital to family- and founder-led businesses to help them sustain and grow their businesses.”
Dr. Wolfgang Büchele, CEO of Exyte, said, “Together with the Stumpf Group and BDT, we will build on the Exyte success story. With our new ownership structure, we will continue to diligently implement our successful strategy with a focus on high-tech industries.”

Public Relations Manager
Samy Abdel Aal
For any further question or should you require additional information please feel free to contact:
Phone: +49 711 88044696
Mobil: +49 172 840 33 01
samy.abdelaal@exyte.net
Please understand that our press office can only answer questions from
journalists. Please refer to our general contact email for contacts on other
matters.
Loading….
ARE YOU LOOKING FOR :

Innovation and Expertise
/201203PHOBLSPharma7-1dark.jpg?w=3840)
People and Stories
.jpg?w=3840)
About us
ARE YOU LOOKING FOR :

Projects
